JP2003528916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528916A5 JP2003528916A5 JP2001572103A JP2001572103A JP2003528916A5 JP 2003528916 A5 JP2003528916 A5 JP 2003528916A5 JP 2001572103 A JP2001572103 A JP 2001572103A JP 2001572103 A JP2001572103 A JP 2001572103A JP 2003528916 A5 JP2003528916 A5 JP 2003528916A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- survival
- sigma receptor
- receptor ligand
- endothelial cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 210000002889 endothelial cell Anatomy 0.000 description 9
- 239000003982 sigma receptor ligand Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- UUKPIWYXWLJPJF-UHFFFAOYSA-N 2-(2-adamantyl)-1-(4-iodophenyl)guanidine Chemical compound C1C2CC(C3)CC1CC3C2N=C(N)NC1=CC=C(I)C=C1 UUKPIWYXWLJPJF-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- GUDVQJXODNJRIJ-CALCHBBNSA-N 9-[3-[(3S,5R)-3,5-dimethyl-1-piperazinyl]propyl]carbazole Chemical compound C1[C@@H](C)N[C@@H](C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 GUDVQJXODNJRIJ-CALCHBBNSA-N 0.000 description 1
- ZWHRZGHGYMUSRM-VWDRLOGHSA-N 9-[3-[(3r,5s)-3,5-dimethylpiperazin-1-yl]propyl]carbazole;hydron;dichloride Chemical compound Cl.Cl.C1[C@@H](C)N[C@@H](C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 ZWHRZGHGYMUSRM-VWDRLOGHSA-N 0.000 description 1
- PPMGNFFGNNRYQC-UHFFFAOYSA-N 9h-carbazole;dihydrochloride Chemical compound Cl.Cl.C1=CC=C2C3=CC=CC=C3NC2=C1 PPMGNFFGNNRYQC-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010059053 Shunt stenosis Diseases 0.000 description 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 1
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 1
- 229940094948 Sigma receptor agonist Drugs 0.000 description 1
- 229940122490 Sigma receptor antagonist Drugs 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- LGQCVMYAEFTEFN-UHFFFAOYSA-N n-allylnormetazocine Chemical group C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C)CC2 LGQCVMYAEFTEFN-UHFFFAOYSA-N 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229950004933 rimcazole Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0007842.8 | 2000-03-31 | ||
| GBGB0007842.8A GB0007842D0 (en) | 2000-03-31 | 2000-03-31 | Sigma receptor ligands and their medical uses |
| PCT/GB2001/001495 WO2001074359A1 (en) | 2000-03-31 | 2001-04-02 | Sigma receptor ligands and their medical uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528916A JP2003528916A (ja) | 2003-09-30 |
| JP2003528916A5 true JP2003528916A5 (enExample) | 2008-05-15 |
Family
ID=9888850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572103A Pending JP2003528916A (ja) | 2000-03-31 | 2001-04-02 | シグマレセプターリガンド及びその医学的使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040019060A1 (enExample) |
| EP (1) | EP1267875A1 (enExample) |
| JP (1) | JP2003528916A (enExample) |
| AU (1) | AU4436701A (enExample) |
| GB (1) | GB0007842D0 (enExample) |
| WO (1) | WO2001074359A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060052386A1 (en) * | 2003-06-12 | 2006-03-09 | Tadeusz Wieloch | Sigma ligands for neuronal regeneration and functional recovery |
| EP1635805A4 (en) * | 2003-06-12 | 2007-08-08 | Ms Science Corp | SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT |
| US7994214B2 (en) | 2003-08-29 | 2011-08-09 | Lifecycle Pharma A/S | Solid dispersions comprising tacrolimus |
| ES2376238T3 (es) | 2003-08-29 | 2012-03-12 | Veloxis Pharmaceuticals A/S | Composiciones de liberación modificada comprendiendo tacrolimus. |
| GB0419145D0 (en) * | 2004-08-27 | 2004-09-29 | Univ Dundee | Treatment of posterior capsule opacification |
| DE102004054552A1 (de) | 2004-11-11 | 2006-05-18 | Hcb Happy Child Birth Holding Ag | Neue Zusammensetzung zur Erleichterung der Humangeburt |
| EP1787679A1 (en) * | 2005-07-29 | 2007-05-23 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20070160975A1 (en) * | 2006-01-09 | 2007-07-12 | University Of South Florida | Method for the Identification of Drugs to Treat Stroke at Delayed Timepoints |
| CA2643199A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP2066355A2 (en) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
| US12083103B2 (en) | 2007-05-30 | 2024-09-10 | Veloxis Pharmaceuticals, Inc. | Tacrolimus for improved treatment of transplant patients |
| PL2167033T4 (pl) | 2007-05-30 | 2018-08-31 | Veloxis Pharmaceuticals A/S | Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus |
| EP3106166B1 (en) | 2008-02-29 | 2020-12-02 | VM Therapeutics LLC | Compounds for treating pain syndrome and other disorders |
| US12403095B2 (en) | 2008-05-30 | 2025-09-02 | Veloxis Pharmaceuticals, Inc. | Stabilized tacrolimus composition |
| WO2010015040A1 (en) * | 2008-08-07 | 2010-02-11 | Powmri Ltd | Therapy and prevention of tdp-43 proteinopathy |
| GB0821093D0 (en) * | 2008-11-18 | 2008-12-24 | Modern Biosciences Plc | Treatment |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2010101649A2 (en) * | 2009-03-05 | 2010-09-10 | Pablo Gastaminza | Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection |
| GB0907973D0 (en) | 2009-05-08 | 2009-06-24 | Modern Biosciences Plc | Combination therapy |
| ES2591352T3 (es) | 2010-02-17 | 2016-11-28 | Veloxis Pharmaceuticals A/S | Composición de tacrolimus estabilizada |
| US20110288101A1 (en) * | 2010-05-21 | 2011-11-24 | Alcon Research, Ltd. | Surgical compositions containing sigma-receptor agonists |
| FR2970869B1 (fr) * | 2011-01-31 | 2013-09-06 | Centre Nat Rech Scient | Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel |
| AU2024320717A1 (en) | 2023-08-04 | 2026-03-05 | Kyrexa Ltd | Use of rimcazole to treat cancer |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3852456A (en) * | 1973-08-24 | 1974-12-03 | S Silverman | Method for controlling psoriasis |
| US4454151A (en) * | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
| US5202116A (en) * | 1989-04-10 | 1993-04-13 | Oncogen | Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m |
| US5849760A (en) * | 1993-12-09 | 1998-12-15 | Institut De Recherche Jouveinal | 2-(arylalkenyl)azacycloalkane derivatives as ligands for sigma receptors |
| AU3138595A (en) * | 1994-07-20 | 1996-02-16 | Acea Pharmaceuticals, Inc. | Haloperidol analogs and the use thereof |
| DE69535673D1 (de) * | 1994-08-30 | 2008-02-07 | Univ Dundee | Mittel zur induktion von apoptosis und zur therapieanwendung |
| US5792748A (en) * | 1995-06-07 | 1998-08-11 | The General Hospital Corporation | Method for inhibiting neoplastic disease in mammals |
| GB9814036D0 (en) * | 1998-06-29 | 1998-08-26 | Univ Dundee | Materials and methods relating to the induction of apoptosis in target cells |
-
2000
- 2000-03-31 GB GBGB0007842.8A patent/GB0007842D0/en not_active Ceased
-
2001
- 2001-04-02 JP JP2001572103A patent/JP2003528916A/ja active Pending
- 2001-04-02 WO PCT/GB2001/001495 patent/WO2001074359A1/en not_active Ceased
- 2001-04-02 US US10/240,327 patent/US20040019060A1/en not_active Abandoned
- 2001-04-02 AU AU44367/01A patent/AU4436701A/en not_active Abandoned
- 2001-04-02 EP EP01917284A patent/EP1267875A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2746537B2 (ja) | 組合せ薬剤 | |
| AR041262A1 (es) | Metodos para tratar los trastornos de ojo seco | |
| RU96107040A (ru) | Многоединичный фармацевтический препарат, содержащий ингибитор протонного насоса | |
| Cody et al. | Age-related hemodynamic, renal, and hormonal differences among patients with congestive heart failure | |
| RU96112148A (ru) | Антагонисты рецепторов эндотелина | |
| KR20170005163A (ko) | 디펩티딜 펩티다제 ⅳ 억제제의 용도 | |
| CN102223884B (zh) | 固体药物组合物 | |
| DE19875011I2 (de) | Verwendung von Sertindol zur Behandlung von Schiz ophrenie. | |
| Corboz et al. | Pharmacological characterization of postjunctional α-adrenoceptors in human nasal mucosa | |
| ATE338549T1 (de) | Therapeutische zusammensetzung von amlodipin und benazepril / benazeprilat | |
| ATE365550T1 (de) | Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie | |
| JP2005527523A5 (enExample) | ||
| EP3297991B1 (en) | Novel amidoheteroaryl aroyl hydrazide ethynes | |
| RU2003131970A (ru) | Производные 4-(фенил-пиперидин-4-илиден-метил)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств | |
| RU2003131971A (ru) | Производные 4-(фенил-пиперидин-4-илиден-метил)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств | |
| EP3090744A1 (en) | Pharmaceutical complex formulation comprising angiotensin ii receptor blocker and hmg-coa reductase inhibitor | |
| US6174910B1 (en) | AT1 receptor antagonist for the stimulation of apoptosis | |
| Wu et al. | Recent progress in the Research on Benzimidazole PARP-1 inhibitors | |
| Corti et al. | The beauty and the beast: aspects of the autonomic nervous system | |
| Kellow | The renin‐angiotensin system and angiotensin convertin enzyme (ACE) inhibitors. | |
| Kevelaitis et al. | Na+/H+ exchange inhibition in hypertrophied myocardium subjected to cardioplegic arrest: an effective cardioprotective approach | |
| Frishman et al. | α-Adrenergic blockers | |
| KR20000016406A (ko) | 울혈성 심장 마비 치료용 제제 및 방법_ | |
| Mirkhani et al. | Comparison of the effects of levosimendan and papaverine on human internal mammary artery and saphenous vein | |
| JPWO2002032881A1 (ja) | 新規血管狭窄治療剤または予防剤 |